Lidia Fonseca - Pfizer Executive Officer
| PFE Stock | 11.78 0.04 0.34% |
Executive
Lidia Fonseca is Executive Officer of Pfizer Inc CDR
| Age | 55 |
| Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.0331 % which means that it generated a profit of $0.0331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0454 %, meaning that it generated $0.0454 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Pfizer's Net Tangible Assets are very stable compared to the past year. As of the 12th of December 2024, Total Current Assets is likely to grow to about 49.9 B, while Total Assets are likely to drop about 199.2 B. Pfizer Inc CDR (PFE) is traded on NEO Exchange in Canada and employs 88,000 people. Pfizer is listed under Pharmaceuticals category by Fama And French industry classification.Management Performance
| Return On Equity | 0.0454 | ||||
| Return On Asset | 0.0331 |
Pfizer Inc CDR Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Advisor | ||
| Jennifer Damico, Controller VP | ||
| Aamir Malik, Executive Officer | ||
| DVM DVM, Chairman CEO | ||
| Frank DAmelio, CFO VP | ||
| Sally Susman, Executive Officer | ||
| Douglas Lankler, Executive Counsel | ||
| Rady Johnson, Quality Compliance | ||
| Mikael MD, Chief Development | ||
| Albert DVM, Chairman CEO | ||
| Payal Becher, Chief VP | ||
| Christopher CFA, VP Officer | ||
| Andreas Panayiotou, Global Officer | ||
| Francesca DeMartino, Chief Officer | ||
| Lidia Fonseca, Executive Officer | ||
| Angela Hwang, Chief Bus | ||
| David Denton, Chief VP | ||
| Annette Doherty, Head Sciences |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0454 | ||||
| Return On Asset | 0.0331 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 285.73 B | ||||
| Shares Outstanding | 16.69 B | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 3.42 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B |
Pair Trading with Pfizer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.Moving together with Pfizer Stock
Moving against Pfizer Stock
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Pfizer Stock
Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.